In contrast to normal cells where activation of STAT3 is only transient due to a host of endogenous protein regulators (e.g., PIAS, SOCS), aberrant and constitutive activation of STAT3 has been detected in a wide variety of human cancers, including solid tumors as well as blood malignancies [4]. Here, STAT3 is linked to cancer.